Nifurantin (Nitrofurantoin)

Nitrofurantoin, the active ingredient in Nifurantin, is a nitrofuran antibiotic presented as an oral tablet for systemic use. It works by inhibiting bacterial enzymes and damaging DNA, leading to bacteriostatic or bactericidal activity. The drug is indicated for the treatment of uncomplicated urinary tract infections, such as cystitis, in adult patients.

GNH USA supplies Nifurantin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels across the European Union and other global markets, ensuring quality and regulatory compliance.

Nitrofurantoin is used to treat bacterial infections of the urinary tract.

Uncomplicated urinary tract infection: eliminates susceptible bacteria, relieving symptoms and preventing progression. Cystitis: resolves bladder infection, reducing dysuria and urinary frequency. Recurrent urinary tract infection prophylaxis: may be prescribed to reduce recurrence in patients with a history of repeated infections.

Nitrofurantoin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Metallic taste

Serious or Rare Side Effects: - Pulmonary toxicity (interstitial pneumonitis, fibrosis) - Hepatic injury (hepatitis, jaundice) - Severe allergic reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Hemolytic anemia in patients with glucose‑6‑phosphate dehydrogenase deficiency

Before prescribing Nitrofurantoin, clinicians should consider several safety factors.

Renal function assessment: avoid use in patients with creatinine clearance below 60 mL/min. Pregnancy considerations: safety not established; use only if clearly needed. G6PD deficiency: risk of hemolysis; screen before therapy. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Nitrofurantoin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption; separate dosing by at least 2 hours. - Probenecid: decreases renal excretion, increasing plasma levels; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Methenamine: additive urinary tract irritation; monitor symptoms. - Fluoroquinolones: overlapping toxicity; assess risk.